Health Trials

About this trial

This is an open label randomized controlled trial for patients with methicillin resistant S. aureus (MRSA) bloodstream infection which will directly compare the two most commonly used therapies, vancomycin and daptomycin.

This study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119)

Eligibility criteria

Qualifiers

None

Disqualifiers

Methicillin-resistant S. aureus bacteremia

Severe allergy or non-severe rash to vancomycin or daptomycin

Suspected or confirmed MRSA pneumonia

Known vancomycin minimum inhibitory concentration (MIC) greater than or equal to 2mg/L or daptomycin MIC greater than or equal to 1mg/L

Trial design

Treatments tested in this trial

  • Daptomycin for Injection
  • Vancomycin (IV)

Treatment groups

300 Participants
are divided into 2 treatment groups

Locations

17
Australia
Concord Repatriation and General Hospital2139, ConcordNew South Wales, Australia
John Hunter Hospital2305, NewcastleNew South Wales, Australia
Westmead Hospital2145, WestmeadNew South Wales, Australia
Royal Brisbane and Women's Hospital4029, HerstonQueensland, Australia

Sponsors and collaborators

Todd C. Lee MD MPH FIDSA

Lead sponsor

McGill University Health Centre/Research Institute of the McGill University Health Centre

Sponsor institution

University of Melbourne

Collaborator

The Peter Doherty Institute for Infection and Immunity

Collaborator

Source ClinicalTrials.gov